Aspire Biopharma Faces Delisting Notice

Ticker: ASBPW · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1847345

Sentiment: bearish

Topics: delisting, listing-standards, corporate-actions

Related Tickers: ASBP

TL;DR

ASBP got a delisting notice, might be trouble.

AI Summary

Aspire Biopharma Holdings, Inc. filed an 8-K on October 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing also includes financial statements and exhibits. The company was formerly known as PowerUp Acquisition Corp. and PowsedrUp Acquisition Corp., with a name change on February 22, 2021.

Why It Matters

This filing indicates potential issues with Aspire Biopharma's continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event that can lead to stock suspension or removal from an exchange.

Key Players & Entities

FAQ

What specific rule or standard has Aspire Biopharma Holdings, Inc. failed to satisfy?

The filing indicates a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule or standard in the provided text.

What is the exact date of the earliest event reported in this 8-K filing?

The earliest event reported is dated October 15, 2025.

When was Aspire Biopharma Holdings, Inc. formerly known as PowerUp Acquisition Corp.?

The company changed its name from PowerUp Acquisition Corp. on February 22, 2021.

What is the SIC code for Aspire Biopharma Holdings, Inc.?

The Standard Industrial Classification (SIC) code for Aspire Biopharma Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the state of incorporation for Aspire Biopharma Holdings, Inc.?

Aspire Biopharma Holdings, Inc. is incorporated in Delaware.

Filing Stats: 914 words · 4 min read · ~3 pages · Grade level 13.4 · Accepted 2025-10-17 17:15:41

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRE BIOPHARMA HOLDINGS, INC. Dated: October 17, 2025 By: /s/ Kraig Higginson Kraig Higginson Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing